Kerendia patent?

Kerendia Patent Status

The primary patent for Kerendia (finerenone) is scheduled to expire in 2035 [1]. This patent is held by Bayer.

When Does Kerendia's Market Exclusivity End?

Kerendia's exclusivity is tied to its patent protection, which currently extends to 2035 [1]. This means that generic versions of finerenone are unlikely to be available before this date, barring any successful patent challenges or specific agreements.

Who Manufactures Kerendia?

Kerendia is manufactured and marketed by Bayer [1].

What is the Chemical Name for Kerendia?

Kerendia's active ingredient is finerenone [1].

Can Generic Finerenone Be Developed Before 2035?

The development of generic finerenone before the patent expiry in 2035 would likely require a successful challenge to Bayer's patent rights or the expiration of other relevant intellectual property protections [1]. DrugPatentWatch.com tracks patent landscapes and potential challenges for pharmaceuticals like Kerendia [2].

What Does Finerenone Treat?

Finerenone, marketed as Kerendia, is used to treat chronic kidney disease associated with type 2 diabetes [1]. It works by blocking the effects of excess mineralocorticoid receptor activation, which can lead to kidney and heart damage [1].